Gene transfer to skeletal muscle by site-specific delivery of electroporation and ultrasound

Li, Yuanli; Wang, Junqing; Satterle, Andrew; Wu, Qunqiang; Wang, Jue; Liu, Feng

doi:10.1016/j.bbrc.2012.06.090

Cited by 19 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What is more, US was also revealed to be able to enhance the uptake of drugs, proteins, DNA/RNA, and other compounds into cells and tissues [25,26,27]. It has been reported that US was an efficient, safe and simple nonviral physical method of DNA delivery in vivo by its ability to increase cell membrane permeability [28]. In this study, US significantly increased the expression of CD151.…”

Section: Discussionmentioning

confidence: 63%

Delivery of CD151 by Ultrasound Microbubbles in Rabbit Myocardial Infarction

Yang

Tang²,

Tao³

et al. 2016

Cardiology

View full text Add to dashboard Cite

Objectives: We aimed to evaluate whether ultrasound (US) and microbubble-mediated delivery of Cluster of Differentiation 151 (CD151) could enhance the therapeutic effects of CD151 on myocardial infarction (MI). Methods: A rabbit model of MI was established by a modified Fujita method. Then, 50 MI rabbits were randomly divided into 5 groups, including G1 (CD151 plasmid and physiological saline in the presence of US); G2 (CD151 and Sonovue in the presence of US); G3 (CD151 and Sonovue in the absence of US); G4 (Sonovue in the absence of US), and a control group (physiological saline in the absence of US). After 14 days of treatment, the expression of CD151 was detected by Western blot. Besides, vessel density of peri-infarcted myocardium was measured by immunohistochemistry, and cardiac function was analyzed by echocardiography. Results: The rabbit model of MI was established successfully. CD151 injection increased the expression of CD151 and microvessel density in the myocardium of MI rabbits. Heart function was significantly improved by CD151, which exhibited increased left ventricular ejection fraction, left ventricular fractional shortening and a reduced Tei index. Besides, US Sonovue significantly increased the expression efficiency of CD151. Conclusion: US microbubble was an effective vector for CD151 delivery. CD151 might be an effective therapeutic target for MI.

show abstract

Section: Discussionmentioning

confidence: 63%

Delivery of CD151 by Ultrasound Microbubbles in Rabbit Myocardial Infarction

Yang

Tang²,

Tao³

et al. 2016

Cardiology

View full text Add to dashboard Cite

show abstract

“…So far, clinical trials of naked DNA for cancer treatment using in vivo electroporation have been initiated in patients with melanoma and prostate cancer ( Table 2) [38]. However, up to now, skeletal muscle still is the most promising administration site for electroporation [39], because it has been reported that the ability of plasmid DNA to transfect other cells such as ocular/ retinal cells are negative with little-to-no transfection or gene expression [40,41].…”

Section: Naked Dnamentioning

confidence: 98%

Emerging biotechnological strategies for non-viral antiangiogenic gene therapy

Liu

Zhang

2012

Angiogenesis

View full text Add to dashboard Cite

Angiogenesis has emerged as a promising target of cancer treatment. With the development of biotechnology, major progress has been made in the exploring effective therapies on targeting tumor angiogenesis over the last 20 years. Gene therapy has attracted considerable interest by virtue of the capabilities of expressing sustained levels of therapeutic agents within cells of the patients. However, the major challenge of gene therapy is the efficient delivery of therapeutic gene to the target site. Compared with viral strategies, non-viral strategies were more acceptable by their widely recognized security and lower side effects. This paper reviews the basic biology of angiogenesis, the potential advantages of antiangiogenic gene therapy, the therapeutic genetic drugs developed through biotechnology, as well as the biotechnological strategies that enhancing non-viral gene therapy targeting to tumor angiogenesis in a more controlled manner, with great respect to RNA interference, ligand-directed vascular targeting strategies, vascular endothelial growth factor pathway and tumor associated macrophages targeting. In conclusion, antiangiogenic gene therapy holds great promise in advancing cancer therapy. Developing better non-viral biotechnological platforms will benefit antiangiogenic targeted cancer gene therapeutic methods, support their evaluation in human clinical trials and realize the actual utilization in the near future.

show abstract

“…Several nonviral methods may be used to deliver DNAs or proteins into animals, and some of these methods are under testing for use in humans. These methods include different nanoparticles and cell penetration peptides, and more in‐depth information on in vivo delivery methods can be found in related reviews . These methods can be applied, at least in principle, for in vivo delivery of the engineered PUF factors.…”

Section: Current and Future Applications Of Engineered Rbpsmentioning

confidence: 99%

“…These methods include different nanoparticles and cell penetration peptides, and more in-depth information on in vivo delivery methods can be found in related reviews. [99][100][101] These methods can be applied, at least in principle, for in vivo delivery of the engineered PUF factors. As the application of engineered PUF factors is still in early stages, we expect the technology for protein delivery to advance ahead of the in vivo application of these factors in live animals or humans.…”

Section: In Vivo Delivery Of Engineered Rbpsmentioning

confidence: 99%

Engineering RNA‐binding proteins with diverse activities

Wei

Wang

2015

WIREs RNA

View full text Add to dashboard Cite

With generations of efforts to understand RNA functions in diverse cellular processes, RNA-binding proteins (RBPs) have emerged to be one of the central players in regulating RNA-related pathways. RBPs control almost all aspects of RNA processing via recognizing their RNA target(s). Most of these proteins have a modular configuration, with one or more RNA-binding domain for target recognition and various functional modules to affect the metabolism and biological functions of RNA. Thus, engineering RNA-binding factors with customized specificity and function is extremely useful in biological and medical research. In this review, we discuss the current advances in engineering RBPs that specifically bind to diverse targets, with emphasis on the design strategies and their applications as new biological tools in various aspects of RNA metabolism and function.

show abstract

Gene transfer to skeletal muscle by site-specific delivery of electroporation and ultrasound

Cited by 19 publications

References 51 publications

Delivery of CD151 by Ultrasound Microbubbles in Rabbit Myocardial Infarction

Delivery of CD151 by Ultrasound Microbubbles in Rabbit Myocardial Infarction

Emerging biotechnological strategies for non-viral antiangiogenic gene therapy

Engineering RNA‐binding proteins with diverse activities

Contact Info

Product

Resources

About